Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Extracellular Matrix Proteins | 5 | 2015 | 68 | 0.940 |
Why?
|
| Transforming Growth Factor beta | 5 | 2015 | 183 | 0.870 |
Why?
|
| Gaucher Disease | 1 | 2016 | 3 | 0.590 |
Why?
|
| Proteoglycans | 3 | 2014 | 46 | 0.520 |
Why?
|
| Long-Term Potentiation | 2 | 2005 | 99 | 0.470 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2009 | 91 | 0.440 |
Why?
|
| Estradiol | 1 | 2014 | 244 | 0.430 |
Why?
|
| Transcription, Genetic | 2 | 2014 | 550 | 0.420 |
Why?
|
| Osteosarcoma | 1 | 2009 | 24 | 0.350 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 42 | 0.340 |
Why?
|
| Extracellular Matrix | 3 | 2004 | 111 | 0.330 |
Why?
|
| Peptide Fragments | 1 | 2009 | 298 | 0.300 |
Why?
|
| Apoptosis | 3 | 2015 | 1317 | 0.300 |
Why?
|
| Chondrocytes | 4 | 2014 | 15 | 0.290 |
Why?
|
| Versicans | 5 | 2010 | 7 | 0.290 |
Why?
|
| Fibroblasts | 3 | 2016 | 252 | 0.250 |
Why?
|
| Electroencephalography | 1 | 2005 | 108 | 0.250 |
Why?
|
| Cell-Matrix Junctions | 1 | 2003 | 2 | 0.240 |
Why?
|
| Theta Rhythm | 1 | 2003 | 7 | 0.230 |
Why?
|
| Hippocampus | 2 | 2005 | 546 | 0.230 |
Why?
|
| Oligopeptides | 1 | 2003 | 97 | 0.220 |
Why?
|
| Animals | 15 | 2016 | 14307 | 0.210 |
Why?
|
| Muscle, Skeletal | 1 | 2003 | 257 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 592 | 0.190 |
Why?
|
| Cell Adhesion | 5 | 2003 | 209 | 0.190 |
Why?
|
| Cell Line | 3 | 2015 | 1289 | 0.160 |
Why?
|
| Integrins | 2 | 2009 | 49 | 0.150 |
Why?
|
| Pyrrolidines | 1 | 2016 | 26 | 0.140 |
Why?
|
| Exons | 2 | 2014 | 80 | 0.140 |
Why?
|
| Dogs | 1 | 2016 | 138 | 0.140 |
Why?
|
| Kinetics | 1 | 2016 | 650 | 0.130 |
Why?
|
| 5' Flanking Region | 1 | 2014 | 4 | 0.130 |
Why?
|
| Papio | 1 | 2014 | 21 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 396 | 0.120 |
Why?
|
| Retroviridae | 1 | 2014 | 22 | 0.120 |
Why?
|
| Oxidative Stress | 2 | 2010 | 874 | 0.120 |
Why?
|
| Response Elements | 1 | 2014 | 52 | 0.120 |
Why?
|
| Conserved Sequence | 1 | 2014 | 106 | 0.120 |
Why?
|
| Alternative Splicing | 1 | 2014 | 82 | 0.120 |
Why?
|
| Electric Stimulation | 2 | 2005 | 177 | 0.120 |
Why?
|
| Genes, Reporter | 1 | 2014 | 132 | 0.120 |
Why?
|
| Amino Acid Sequence | 2 | 2009 | 1124 | 0.120 |
Why?
|
| Genetic Vectors | 1 | 2014 | 154 | 0.120 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 136 | 0.120 |
Why?
|
| RNA, Messenger | 3 | 2014 | 1152 | 0.110 |
Why?
|
| Analysis of Variance | 3 | 2010 | 528 | 0.110 |
Why?
|
| Transfection | 1 | 2014 | 496 | 0.110 |
Why?
|
| Estrogens | 1 | 2014 | 190 | 0.110 |
Why?
|
| Retina | 1 | 2015 | 255 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 484 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2015 | 296 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2014 | 347 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2003 | 283 | 0.100 |
Why?
|
| Macrophages | 1 | 2015 | 431 | 0.100 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2010 | 33 | 0.090 |
Why?
|
| Humans | 11 | 2016 | 34853 | 0.090 |
Why?
|
| Macrophages, Peritoneal | 1 | 2009 | 22 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 1534 | 0.090 |
Why?
|
| Receptors, LDL | 1 | 2009 | 30 | 0.090 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 36 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2010 | 2128 | 0.090 |
Why?
|
| Cells, Cultured | 4 | 2009 | 1442 | 0.090 |
Why?
|
| Prostatic Hyperplasia | 1 | 2009 | 33 | 0.080 |
Why?
|
| Rats | 3 | 2005 | 3261 | 0.080 |
Why?
|
| Proteomics | 1 | 2010 | 302 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2010 | 859 | 0.080 |
Why?
|
| Female | 7 | 2014 | 19873 | 0.080 |
Why?
|
| Atherosclerosis | 1 | 2009 | 131 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2009 | 159 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2007 | 66 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 303 | 0.070 |
Why?
|
| Biocompatible Materials | 2 | 2004 | 75 | 0.070 |
Why?
|
| Mice | 4 | 2009 | 5668 | 0.070 |
Why?
|
| Texas | 1 | 2008 | 299 | 0.070 |
Why?
|
| Cycloheximide | 2 | 2003 | 30 | 0.070 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2007 | 84 | 0.070 |
Why?
|
| Fibronectins | 2 | 2003 | 65 | 0.070 |
Why?
|
| Protein Binding | 1 | 2009 | 913 | 0.070 |
Why?
|
| Polyesters | 2 | 2004 | 21 | 0.070 |
Why?
|
| Rural Population | 1 | 2008 | 253 | 0.070 |
Why?
|
| Mexican Americans | 1 | 2008 | 177 | 0.070 |
Why?
|
| Male | 6 | 2009 | 18870 | 0.070 |
Why?
|
| Hydrogels | 2 | 2004 | 33 | 0.070 |
Why?
|
| Polyethylene Glycols | 2 | 2004 | 80 | 0.070 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2005 | 1 | 0.070 |
Why?
|
| Disintegrins | 1 | 2005 | 2 | 0.070 |
Why?
|
| Extracellular Space | 1 | 2005 | 33 | 0.070 |
Why?
|
| Metalloendopeptidases | 1 | 2005 | 15 | 0.070 |
Why?
|
| Ovulation | 1 | 2005 | 20 | 0.070 |
Why?
|
| Electrophysiology | 1 | 2005 | 130 | 0.060 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2005 | 75 | 0.060 |
Why?
|
| Ovarian Follicle | 1 | 2005 | 31 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 528 | 0.060 |
Why?
|
| Osteogenesis | 1 | 2004 | 31 | 0.060 |
Why?
|
| Tenascin | 1 | 2004 | 6 | 0.060 |
Why?
|
| Chondroitin Sulfates | 1 | 2004 | 9 | 0.060 |
Why?
|
| Oocytes | 1 | 2005 | 143 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2004 | 75 | 0.060 |
Why?
|
| Hyaluronic Acid | 1 | 2004 | 33 | 0.060 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2003 | 34 | 0.060 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 37 | 0.060 |
Why?
|
| Edetic Acid | 1 | 2003 | 21 | 0.060 |
Why?
|
| Histocytochemistry | 1 | 2003 | 45 | 0.060 |
Why?
|
| Collagen Type I | 1 | 2003 | 27 | 0.060 |
Why?
|
| Myoblasts | 1 | 2003 | 25 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 125 | 0.060 |
Why?
|
| Mesoderm | 1 | 2003 | 70 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2003 | 123 | 0.060 |
Why?
|
| Laminin | 1 | 2003 | 59 | 0.060 |
Why?
|
| Muscle Development | 1 | 2003 | 44 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2003 | 70 | 0.060 |
Why?
|
| Prevalence | 1 | 2008 | 1425 | 0.060 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2003 | 60 | 0.060 |
Why?
|
| Antibodies | 1 | 2003 | 135 | 0.060 |
Why?
|
| Cytological Techniques | 1 | 2002 | 14 | 0.050 |
Why?
|
| Neuronal Plasticity | 1 | 2003 | 102 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 485 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2015 | 1530 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2003 | 834 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2015 | 1802 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1490 | 0.050 |
Why?
|
| Time Factors | 3 | 2014 | 1681 | 0.050 |
Why?
|
| Risk Factors | 1 | 2008 | 3414 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 1426 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2010 | 490 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 605 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2015 | 897 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 1300 | 0.040 |
Why?
|
| Middle Aged | 2 | 2008 | 9642 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 901 | 0.030 |
Why?
|
| Retinal Vessels | 1 | 2015 | 24 | 0.030 |
Why?
|
| Adult | 2 | 2008 | 11034 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 794 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2015 | 122 | 0.030 |
Why?
|
| Lectins, C-Type | 2 | 2004 | 35 | 0.030 |
Why?
|
| Molecular Weight | 2 | 2003 | 161 | 0.030 |
Why?
|
| Cartilage, Articular | 2 | 2002 | 9 | 0.030 |
Why?
|
| Rabbits | 2 | 2003 | 278 | 0.030 |
Why?
|
| Stress, Mechanical | 2 | 2003 | 110 | 0.030 |
Why?
|
| Rotenone | 1 | 2010 | 18 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 41 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 51 | 0.020 |
Why?
|
| Insecticides | 1 | 2010 | 47 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 74 | 0.020 |
Why?
|
| CHO Cells | 1 | 2010 | 107 | 0.020 |
Why?
|
| Cricetinae | 1 | 2010 | 217 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2010 | 101 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 194 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2010 | 128 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 269 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2009 | 19 | 0.020 |
Why?
|
| Streptozocin | 1 | 2009 | 21 | 0.020 |
Why?
|
| Urinalysis | 1 | 2009 | 31 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 122 | 0.020 |
Why?
|
| Proteome | 1 | 2010 | 132 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 75 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 247 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2009 | 46 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2009 | 57 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 2009 | 22 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 445 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 139 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 148 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2009 | 175 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2009 | 56 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2009 | 87 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2009 | 407 | 0.020 |
Why?
|
| Sulfur Radioisotopes | 1 | 2007 | 7 | 0.020 |
Why?
|
| Prostate | 1 | 2009 | 136 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 984 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 818 | 0.020 |
Why?
|
| Sulfates | 1 | 2007 | 23 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 608 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2007 | 139 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 195 | 0.020 |
Why?
|
| RNA | 1 | 2009 | 234 | 0.020 |
Why?
|
| Arteries | 1 | 2007 | 67 | 0.020 |
Why?
|
| Amino Acids | 1 | 2007 | 139 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2007 | 127 | 0.020 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 2005 | 1 | 0.020 |
Why?
|
| Syndecans | 1 | 2005 | 2 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2005 | 15 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2005 | 41 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2005 | 44 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 2004 | 10 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 781 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2004 | 45 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2004 | 48 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 78 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2004 | 43 | 0.020 |
Why?
|
| Materials Testing | 1 | 2004 | 71 | 0.020 |
Why?
|
| Osteopontin | 1 | 2004 | 35 | 0.020 |
Why?
|
| Ovary | 1 | 2005 | 101 | 0.020 |
Why?
|
| Cell Count | 1 | 2004 | 129 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2004 | 202 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2004 | 114 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2004 | 67 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2003 | 44 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 256 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 197 | 0.010 |
Why?
|
| Phalloidine | 1 | 2003 | 1 | 0.010 |
Why?
|
| Rhodamines | 1 | 2003 | 20 | 0.010 |
Why?
|
| Micromanipulation | 1 | 2003 | 11 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 429 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 932 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2003 | 98 | 0.010 |
Why?
|
| Transducers | 1 | 2002 | 12 | 0.010 |
Why?
|
| Mechanics | 1 | 2002 | 3 | 0.010 |
Why?
|
| Elasticity | 1 | 2002 | 38 | 0.010 |
Why?
|
| Absorption | 1 | 2002 | 22 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 480 | 0.010 |
Why?
|
| Tensile Strength | 1 | 2002 | 25 | 0.010 |
Why?
|
| Equipment Design | 1 | 2002 | 127 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2003 | 173 | 0.010 |
Why?
|
| Species Specificity | 1 | 2002 | 233 | 0.010 |
Why?
|
| Tissue Engineering | 1 | 2002 | 59 | 0.010 |
Why?
|
| Calcium | 1 | 2004 | 445 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 562 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 472 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2003 | 360 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 555 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 1422 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2004 | 1349 | 0.010 |
Why?
|
| Water | 1 | 2002 | 283 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 968 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 2333 | 0.010 |
Why?
|
| Aged | 1 | 2004 | 6448 | 0.010 |
Why?
|